<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050293</url>
  </required_header>
  <id_info>
    <org_study_id>538P401</org_study_id>
    <nct_id>NCT04050293</nct_id>
  </id_info>
  <brief_title>Therapy for Migraine Prevention in Children 6-11 Years of Age</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of SPN-538 as a Therapy for the Prevention of Migraine in Subjects Ages 6-11 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in&#xD;
      pediatric patients 6 to 11 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to assess the efficacy and safety of SPN-538 in reducing the monthly migraine&#xD;
      headache frequency in pediatric patients with migraine.&#xD;
&#xD;
      SPN-538 (or matching placebo) will be administered in patients diagnosed with migraine with&#xD;
      or without aura based on the International Headache Society criteria.&#xD;
&#xD;
      The frequency of the migraine attack will be assessed as the primary outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, placebo-controlled, 2-arm, parallel group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of migraine attack per 28 days during the Treatment Phase.</measure>
    <time_frame>28 days</time_frame>
    <description>The primary outcome measure will be recorded daily on an headache electronic diary uploaded on a Patient Reported Outcome (ePRO) application. The electronic diary will serve as the primary tool to collect daily headaches information.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Migraine Disorders</condition>
  <condition>Headache Disorders</condition>
  <arm_group>
    <arm_group_label>SPN-538</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with SPN-538 as a single dose once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be treated with Placebo once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-538</intervention_name>
    <description>Patients will receive SPN-538</description>
    <arm_group_label>SPN-538</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Otherwise, healthy male or female (6 to 11 years of age at the time of screening) with&#xD;
             a history of migraine with or without aura for at least 6 months prior to screening, 3&#xD;
             to 14 headache days (migraine and non-migraine) per month during the 3 months prior to&#xD;
             screening and during Baseline Period, and a PedMIDAS Disability score of &gt; 10 and &lt;&#xD;
             50.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with chronic migraine (&gt;14 headache days per month), cluster headaches, or&#xD;
             migraine aura without headache and, with &gt; 14 headache days during the Baseline&#xD;
             Period.&#xD;
&#xD;
          -  Use of migraine preventive medication other than topiramate within 14 days prior to&#xD;
             the start of the Baseline Period; or used onabotulinumtoxinA (Botox®) 3 months prior&#xD;
             screening and non-pharmacologic complementary and alternative prophylactic approaches&#xD;
             for migraine prevention.&#xD;
&#xD;
          -  Failure to respond to topiramate prophylaxis therapy (2 to 3 mg/kg/day) for a minimum&#xD;
             of 3 months, or to more than 2 clinical trials with an established prophylactic&#xD;
             anti-migraine regimen.&#xD;
&#xD;
          -  Current use or history of antipsychotics, antimanics, barbiturates, benzodiazepines,&#xD;
             muscle relaxants, β-blockers, tricyclic antidepressants, AEDs, calcium channel&#xD;
             blockers, corticosteroids (i.e., systemic, inhaled or topical), daily NSAIDs,&#xD;
             sedatives, serotonin selective reuptake inhibitors (SSRIs), non-selective reuptake&#xD;
             inhibitors (NSRIs), high-dose magnesium supplements (≥600 mg/day), high-dose&#xD;
             riboflavin (≥100 mg/day), calcitonin gene-regulated peptide (CGRP) receptor&#xD;
             antagonists, omega-3, melatonin or cannabidiol (CBD) oil.&#xD;
&#xD;
          -  Overuse of analgesic or migraine-specific agents for acute treatment of migraine (&gt;10&#xD;
             treatment days/month of ergot-containing medications or triptans; or &gt;15 treatment&#xD;
             days/month with simple analgesics (including non steroidal anti-inflammatory drugs&#xD;
             [NSAIDs])&#xD;
&#xD;
          -  Diagnosis of psychiatric disorder (e.g., psychosis, bipolar disorder, major&#xD;
             depression, generalized anxiety disorders), or documented developmental delays or&#xD;
             impairments (e.g., autism, cerebral palsy, or mental retardation).&#xD;
&#xD;
          -  Subjects with seizures or a history of seizure-like events.&#xD;
&#xD;
          -  Known history of visual field defects, neurological disorder or structural disorder of&#xD;
             the brain from birth; head trauma or previous CNS surgery.&#xD;
&#xD;
          -  Evidence of active suicidal ideation and/or suicidal behaviors, pregnancy, active&#xD;
             liver disease or abnormal kidney function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gianpiera Ceresoli-Borroni, PhD</last_name>
    <phone>301-838-2521</phone>
    <email>gceresoliborroni@supenus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Azmi Nasser, PhD</last_name>
    <phone>240-403-5303</phone>
    <email>anasser@supernus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Byrd</last_name>
      <email>lbyrd@cnshealthcare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

